Affiliation:
1. Radiation safety department, Nuclear, and Radiological Safety Research Center, Egyptian Atomic Energy Authority, Cairo, Egypt
2. Drug Radiation Research Department, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt
Abstract
During radiotherapy, immune-modulatory effects of radiation doses should be taken into consideration, not only the anti-tumor radiation effects. Thus, our study aimed to study how γ-radiation modulates immune response in comparison to common immune-suppressive/stimulant agents. Animals were divided into two groups. Category A received Echinacea purpura extract (EP) or irradiated at low radiation doses 0, .25 or .5 Gray (Gy), whereas Category B received cyclophosphamide (CP) or irradiated at high radiation doses 1, 2, or 5 Gy. Serum levels of immunological mediators interleukin-10 (IL-10) and tumor necrosis factor (TNF-α), as well as redox-markers malondialdehyde (MDA) and nitric oxide (NO), hemoglobin (Hgb), white and red blood cells (WBCs, RBCs), and platelet counts were assessed following irradiation. Of the immune-stimulant category, .25 Gy dose offered EP-comparable effects in TNF-α, RBCs, Hgb, and platelet counts cases. As for the immune-suppressive category; 5 Gy irradiation dose induced inflammatory/immunosuppressive responses indicated (rise in NO, TNF-α, and IL-10), and an oxidative stress status (increase in serum MDA). However, 5 Gy γ-irradiation was not observed, herein, as a single immunosuppressive agent. To conclude, during radiotherapy, immunological impact(s) of the used radiation doses should be optimized and followed-up closely to assess the risk/benefit of their usage.
Subject
Chemical Health and Safety,Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health,Toxicology